Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 9:16:1893-1908.
doi: 10.2147/OPTH.S356245. eCollection 2022.

Frequency Doubling Technology Visual Field Loss in Fabry Subjects Related to Retinal Ganglion Cell Function as Explored by ERG and OSOME

Affiliations

Frequency Doubling Technology Visual Field Loss in Fabry Subjects Related to Retinal Ganglion Cell Function as Explored by ERG and OSOME

Langis Michaud et al. Clin Ophthalmol. .

Abstract

Purpose: This study aims to evaluate potential causes of FDT visual field loss in a selected group of Fabry subjects.

Patients and methods: This is a pilot observational study. Subjects were assessed during 2 visits. The following tests were performed: visual acuity, tonometry, optical coherence tomography (OCT) optic nerve scan, frequency doubling time (FDT) and threshold (SAP) VF, ERG, and Online Spectro-reflectometry Oxygenation Measurement in the Eye (OSOME). Results are compared across visits and, when indicated, interpreted against those collected on non-Fabry population matched for age and sex.

Results: The study population was composed of 3 males (34.3 ± 8.9 y.o.) and 5 females (46.4 ± 6.5 y.o). For all subjects, BCVA remained 6/6 OU throughout the study and OCT optic nerve scans were normal. FDT showed a defect in at least 1 quadrant for all participants, in contrast with SAP. FDT PSD value was found different vs SAP. For ERG, the i-wave (52.1 + 2.7 ms) and B-waves (31.6 ± 2.1 ms) peak times were significantly longer compared to a non-Fabry population (p < 0.05). Overall blood oxygenation varied from 61.3% ± 4% to 68.1% ± 4% at the second visit, suggesting a loss of capillary perfusion. Blood volume varied based on location (superior/inferior), eye tested (OD/OS) and time (visit 1/2). The range of values exceeds normal subjects findings (p < 0.05). Blood volume was correlated to FDT PSD value for the superior area of the optic nerve.

Conclusion: The results suggest that Fabry subjects present FDT deficits and abnormal ERG patterns that may be explained by a retinal dysfunction affecting retinal ganglion cells (RGCs), second to vascular alterations.

Keywords: Fabry disease; OSOME; electroretinography; retinal ganglion cells.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Typical corneal verticillata showing pigments and haze.
Figure 2
Figure 2
Bulbar conjunctival vessels tortuosities and micro-aneurysms.
Figure 3
Figure 3
The same blood vessel tortuosities may be seen on the external upper lid.
Figure 4
Figure 4
Arterioles and venules showing tortuosities.
Figure 5
Figure 5
Typical Fabry posterior sub-capsular cataract.
Figure 6
Figure 6
(AD) Evolution of the visual field defects. (A) Patient A OD year 1- no defect; (B) patient A OD year 2- defect in 3 quadrants; (C) patient B OS year 1 - defect in 4 quadrants; (D) patient B OS year 2 – defect in 3/4 quadrants but more severe.
Figure 7
Figure 7
Example of a typical graph showing the relationship between PSD and blood volume.
Figure 8
Figure 8
Example of a typical graph showing the relationship between MD and blood volume.

Similar articles

References

    1. Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. - PubMed
    1. Chan B, Adam DN. A review of Fabry disease. Skin Therapy Letter. 2018;23(2):4–6. - PubMed
    1. Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007;30:68–78. doi:10.1007/s10545-006-0484-8 - DOI - PubMed
    1. MacDermot KD, Holmes A, Miners A. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–760. doi:10.1136/jmg.38.11.750 - DOI - PMC - PubMed
    1. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol. 1979;97:671–676. doi:10.1001/archopht.1979.01020010327008 - DOI - PubMed